Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Granules India is a Hyderabad-based pharmaceutical manufacturer built on vertically integrated, large-volume molecules — paracetamol, metformin, ibuprofen, guaifenesin — spanning APIs, pharmaceutical formulation intermediates (PFIs) and finished dosages. The US generics market is its largest revenue contributor, and it is moving up the value chain into more complex generics and greener API manufacturing. Scale-driven cost leadership in its core molecules is the key moat.
Among the world's largest producers of paracetamol and metformin by volume.
Granules India Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Granules India Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 24.47 | 20.69 | 16.73 |
| Book value / share (₹) | 205.21 | 153.19 | 133.08 |
| Return on equity | 11.7% | 13.5% | 13.2% |
| Return on capital employed | 15.8% | 16.9% | 18.9% |
| Operating margin | 16.6% | 16.1% | 14.4% |
| Net margin | 11.1% | 11.2% | 9.0% |
| EBITDA | ₹1,185 Cr | ₹945 Cr | ₹856 Cr |
| Free cash flow | ₹235 Cr | ₹295 Cr | ₹59 Cr |
| Total debt | ₹1,338 Cr | ₹1,286 Cr | ₹1,223 Cr |
| Debt to equity | 0.26 | 0.35 | 0.38 |
| Interest coverage | 7.8 | 7.0 | 6.1 |
| Current ratio | 1.80 | 1.56 | 1.40 |
| Shares outstanding | 24,78,00,000 | 24,25,40,000 | 24,23,70,000 |
Open the full income statement, balance sheet and cash flow for GRANULES →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.